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ess: nishiyama_o@yahoSummary The prognosis of patients with idiopathic pulmonary fibrosis (IPF) is
generally considered to be poor. As the disease progresses, patients invariably
become severely limited in their activities. Therefore, evaluating the health-related
quality of life (HRQoL) in IPF patients is considered to be important. However, there
have been few studies of this kind to date.
We applied the St. George’s Respiratory Questionnaire (SGRQ) to 41 consecutive
IPF patients and examined various physiological variables to identify factors that
were correlated with the HRQoL.
Total lung capacity, transfer factor, arterial partial pressure of oxygen at rest, the
lowest oxygen saturation during exercise test, and the baseline dyspnoea index (BDI)
score were significantly correlated with the total SGRQ score. A similar tendency was
observed in each component. Conversely, peak oxygen uptake, known as one of the
important factors that determines HRQoL in chronic obstructive pulmonary disease
(COPD), did not correlate with any SGRQ scores. In stepwise multiple regression
analysis, the BDI score was selected as the only factor significantly contributing to
the total SGRQ score.
Dyspnoea was the most important factor determining HRQoL in IPF. The types of
other variables that correlated with the HRQoL in IPF patients were different from
those in COPD.
& 2004 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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HRQoL in IPF patients 409Introduction
Idiopathic pulmonary fibrosis (IPF) is a specific form
of chronic fibrosing interstitial pneumonia limited
to the lung.1 Usual interstitial pneumonia (UIP) is a
histopathological pattern that identifies patients
with IPF.1,2 Recently, the entity of IPF has become
more narrowly defined by the American Thoracic
Society/European Respiratory Society consensus
report.1,3 With these new criteria, the median
survival of IPF/UIP cases was 3–4 years, which was
significantly worse than that of other chronic
interstitial pneumonias.4,5 Thus, the prognosis of
patients with IPF is now proven to be poor. As the
disease progresses, patients invariably become
severely limited in their activities mainly because
of shortness of breath.
In regard to the health-related quality of life
(HRQoL) or health status of IPF patients, there have
been only a few reports, some of which demon-
strated that HRQoL in patients with IPF was more
disturbed than in healthy subjects,6,7 although
which instruments should be used in the evaluation
of these patients is still unknown. Chang et al.8
assessed the validity of several generic and
respiratory-specific HRQoL instruments in patients
with interstitial lung disease (ILD), and reported
that the Medical Outcomes Study Short Form 36
(SF-36) and the St. George’s Respiratory Question-
naire (SGRQ) were better tools. Although the
validity of these instruments for patients with ILD
was demonstrated, the latter study included
patients with a variety of diseases including IPF,
sarcoidosis, and asbestosis.8
The SGRQ was originally developed to assess the
health status of patients with chronic obstructive
pulmonary disease (COPD) and asthma.9 It has
already been shown that the questionnaires are
precise, valid and responsive,9 and the SGRQ has
been used for the evaluation of HRQoL or health
status in patients with COPD and asthma in several
clinical studies. It has been also used for patients
with other diseases such as bronchiectasis and
ILD,8,10 and its validity has been demonstrated.
However, there have been only a few reports that
analysed HRQoL exclusively in IPF patients using
the SGRQ. Although dyspnoea and exercise capacity
are already known to be determining factors of
HRQoL in COPD,11 it remains to be determined
which factors are most important for HRQoL in IPF.
Especially because new criteria for diagnosing IPF
have been recently established,1 it is necessary to
assess the HRQoL in patients with IPF diagnosed
according to these new criteria. The purpose of this
study was to apply the Japanese version of SGRQ to
patients with IPF and to identify the factorssignificantly contributing to their HRQoL, and then
to examine the hypothesis that dyspnoea and
exercise capacity affect their HRQoL.Methods
Study design
The study included 41 consecutive IPF patients who
were referred to or followed by our hospital from
January 2000 through December 2002. UIP was
diagnosed by surgical lung biopsy in 21 patients and
by typical manifestations in chest high-resolution
computed tomographic (CT) findings in another
20.12 The CT images were reviewed by three
experienced observers who reached a decision by
consensus, according to the recent international
consensus statement.1 Pathological diagnoses of
UIP were based on the international consensus
statement of the American Thoracic Society.1
Patients were excluded if they had any of the
following: obstructive lung diseases such as COPD
or asthma, collagen vascular disease, active cor-
onary artery disease, or any other severe morbid
illness. All patients enrolled in the study were
newly diagnosed with IPF and had not received any
treatment, such as corticosteroid or cytotoxic
agents. Patients who were taking long-term oxygen
therapy were excluded. Patients who could not
perform an exercise test on a cycle ergometer were
also excluded.
All patients underwent pulmonary function tests
and an incremental maximal exercise test on a
cycle ergometer. Their HRQoL and dyspnoea rating
were also assessed.
Pulmonary function and exercise capacity
All patients underwent spirometry (CHESTAC-55V;
Chest, Tokyo, Japan), which was calibrated with a
2.0-L syringe, according to the method described in
the American Thoracic Society 1994 update.13 Total
lung capacity (TLC) was obtained using helium
dilution, and the single-breath transfer factor of
the lung for carbon monoxide (TL,CO) was also
measured (CHESTAC-55V; Chest, Tokyo, Japan),
which was corrected for haemoglobin concentra-
tion. The values for slow vital capacity (VC), TLC,
and TL,CO were related to the predicted value.14
An incremental symptom-limited exercise test
was performed on a cycle ergometer (ERGOMETER
232CXL, COMBI, Tokyo, Japan). After 2min of
unloaded cycling, the workload was increased by
10W every minute until the subject could no longer
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O. Nishiyama et al.410continue. During the test, oxygen uptake ð _VO2Þ;
ventilation ð _VEÞ; physiological dead-space tidal
volume ratio (VD/VT) (Centaura-1, Chest, Tokyo,
Japan), and transcutaneous oxygen saturation
(SpO2) were measured, and a 12-lead electrocar-
diogram was obtained. The lowest SpO2 value
during the test was recorded. No patients stopped
the exercise because of arrhythmia or other ECG
abnormalities.Assessment of HRQoL and dyspnoea
HRQoL was assessed by the Japanese version of
SGRQ, which has been previously validated.11 It
provides three-component scores, representing
symptoms, activity, and impacts, and a total score.
Scores for these components and the total score are
on a 100-point scale, with a higher score corre-
sponding to a poorer HRQoL.9
The severity of dyspnoea was assessed using the
Japanese version of the baseline dyspnoea index
(BDI),15 which has also been previously validated.16
The BDI recognizes four grades for each of the
following categories: functional impairment, mag-
nitude of task, and magnitude of effort.15Statistics
Pearson’s correlation coefficients (r) were deter-
mined to examine the degree of correlation amongTable 1 Patient characteristics.
Gender (M/F)
Age (yr)
Height (cm)
Weight (kg)
VC (L)
VC (% pred)
TLC (L)
TLC (% pred)
FEV1 (L)
FEV1 (% pred)
FEV1/FVC (%)
TL,CO (mL/min/mmHg)
TL,CO (% pred)
PaO2 (kPa)
PaCO2 (kPa)
Peak VO2 (mL/min)
The lowest SpO2 during exercise (%)
BDI score (0–12)*
*Possible score 0–12.HRQoL and physiological variables. To investigate
which factors significantly contributed to HRQoL, a
stepwise multiple regression analysis was per-
formed using SGRQ scores as dependent variables.
Variables used as independent variables included
resting VC, TLC, TL,CO, partial arterial oxygen
pressure (PaO2), peak _VO2; the lowest SpO2 during
the exercise test, and BDI score. A P value of less
than 0.05 was considered significant. All values are
presented as mean7SD.Results
Clinical characteristics and HRQoL scores
The clinical characteristics of the patients are
summarized in Table 1. Patients had mild to
moderate decreases in VC, TLC, and reduced
TL,CO.
The scores for each component of the SGRQ are
shown in Table 2. Mild to moderate disturbances
were observed in each component, with the degree
of disturbance especially in the impact component
being relatively mild. The frequency distribution
histograms of SGRQ scores for each component are
shown in Fig. 1. Although some ceiling effects were
observed at the lowest scores (best HRQoL), the
overall scores were almost normally distributed.Mean7SD Range
35/6
6479 39–84
161.078.1 138–185
60.5710.2 41.0–87.7
2.570.7 0.99–3.83
76.6716.8 31.3–102.2
3.971.0 1.74–5.47
77.7718.3 37.0–112.2
2.070.5 0.8–2.9
83.3719.5 44.9–116.6
82.076.6 67.0–95.4
10.673.9 3.1–17.7
58.9720.4 18.2–108.0
11.071.9 6.1–14.8
5.071.1 2.4–9.9
8937314 453–1,572
86.276.6 59.0–96.0
9.172.3 3–12
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Table 2 SGRQ score.
Score, mean7SD Range No. of persons with
Minimum score Maximum score
Symptoms 40.1724.6 4.4–85.6 1 1
Activity 44.5726.7 0–93.9 0 2
Impacts 28.9719.8 0–77.0 0 2
Total 35.7720.6 1.6–77.6 1 1
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Figure 1 Frequency distribution histograms of each score
for the SGRQ. A higher score indicates poorer health.
HRQoL in IPF patients 411Relationships among SGRQ scores,
physiological variables and BDI score
Pearson’s correlation coefficients among SGRQ
scores, physiological variables and the BDI score
are shown in Table 3. Although TLC, TL,CO, PaO2,
the lowest SpO2 during the exercise test, and the
BDI score were significantly correlated with the
total score, VC, PaCO2, and peak _VO2 showed no
significant correlation. The symptom scores were
significantly correlated with VC, TLC, TL,CO, the
lowest SpO2 during the exercise test, and the BDI
score, the activity score with VC, TLC, TL,CO,
PaO2, the lowest SpO2 during the exercise test, and
the BDI score, and the impacts score were
correlated only with the BDI score. The BDI score
showed the most significant correlation with each
score for the SGRQ, however, peak _VO2 was not
correlated with any of the scores. The lowest SpO2
during the exercise test also correlated signifi-
cantly with the symptoms, activity, and total scores
for the SGRQ. The relationship between the BDI
score and the total SGRQ score is shown in Fig. 2.Stepwise multiple regression analyses
The TLC and the BDI score were selected as
independent, significant parameters contributing
to a total explained variation of 39% in the
symptom score. PaO2 and the BDI score were
selected to a total explained variation of 64% in
the activity score. In regard to the impacts and
total scores, the BDI score was only a significant
parameter to 28% and 47%, respectively. VC, TL,CO,
peak _VO2; and the lowest SpO2 during the exercise
test were excluded from the model in each domain
of the SGRQ score (Table 4).Discussion
Evaluating HRQoL in patients with chronic respira-
tory disease is becoming increasingly important,
especially in clinical trials. Two main types of
measurement instruments are available, the gen-
eric and disease-specific questionnaires. In regard
to COPD, some disease-specific instruments have
been developed and used for assessing HRQoL in
patients with COPD. However, no disease-specific
instruments have been developed specifically for
patients with IPF. Chang et al.8 assessed HRQoL in
patients with ILD, including IPF patients, and
evaluated which instrument was the best for
evaluating such patients. Since their findings
suggested that the SGRQ score was most strongly
associated with all the physiological measure-
ments, they concluded that the SGRQ was the best
disease-specific instrument for assessing HRQoL in
ILD patients.8 They also demonstrated that forced
vital capacity (FVC), forced expiratory volume in 1 s
(FEV1), TLC, TL,CO, 6-min walking distance, and
dyspnoea assessed with the Borg dyspnoea score
were significantly correlated with the total SGRQ
score.8 Although the validity of these instruments
for patients with ILD also seemed to be proven, this
study included patients with a variety of diseases
ARTICLE IN PRESS
Table 3 Spearman’s correlation coefficients between the score of the SGRQ and other variables.
Symptoms Activity Impacts Total
VC (L) 0.35z 0.36z 0.15 0.30
TLC (L) 0.48z 0.38z 0.21 0.36z
TL,CO (mL/min/mmHg) 0.32z 0.45z 0.27 0.39z
PaO2 (kPa) 0.21 0.48z 0.29 0.37z
PaCO2 (kPa) 0.05 0.08 0.03 0.02
Peak VO2 (mL/min) 0.14 0.30 0.07 0.19
The lowest SpO2 during exercise 0.38z 0.48z 0.22 0.37z
BDI score 0.55y 0.77* 0.53y 0.69*
Single regression analysis by Pearson’s correlation coefficients; r values are shown.
*Po0:0001; yPo0:001; zPo0:01; zPo0:05:
0
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Figure 2 Scatterplots of the BDI score and the total SGRQ
score. Significant correlation was observed between the
two (R ¼ 0:69; Po0:0001).
O. Nishiyama et al.412such as IPF, sarcoidosis, and asbestosis. Thus, the
present study used the SGRQ exclusively for IPF
patients and then evaluated the factors related to
their HRQoL.
In the present study, TLC, TL,CO, PaO2 at rest,
the lowest SpO2 during the exercise test, and the
BDI score were significantly correlated with the
total SGRQ score. The BDI score was the most
significantly correlated factor among these vari-
ables, and a similar tendency was observed in the
symptoms, activity, and impact components.
Furthermore, in stepwise multiple regression ana-
lysis, the BDI score was selected as the factor
contributing most significantly to all component
scores for the SGRQ. For the impacts and the total
score, BDI was the only contributing factor. Hence,
the present study makes it clear that dyspnoea is
the most important factor determining HRQoL in
patients with IPF.
When treating patients with IPF, impairment in
physiological variables, such as pulmonary function
and PaO2, are usually the main focus. However, in
the present study, dyspnoea rating predicted their
HRQoL more accurately than physiological vari-ables. Although it is unknown whether HRQoL
affects the survival of patients with IPF, considera-
tion of HRQoL is definitely becoming another
important aspect in the treatment of IPF patients.
To our knowledge, the present study is the first
study to clarify the detailed relationships between
HRQoL and physiological variables in IPF, and to
provide strong evidence of the importance of
dyspnoea. The same tendencies have been re-
ported in COPD studies,11,17 and it also becomes
evident in the present study that dyspnoea has a
great impact on HRQoL in patients with not only
COPD but also IPF. Moreover, the level of dyspnoea
has been reported to be one of the independent
factors predicting survival.5 Therefore, manage-
ment of patient dyspnoea should be given greater
emphasis in clinical settings.
Although Chang et al.8 demonstrated that ex-
ercise capacity assessed by a 6-min walking test
was highly correlated with the total SGRQ score,
peak _VO2 was not correlated with any scores for the
SGRQ in our study. Peak _VO2; however, shows
maximal capacity during high-intensity exercise
whereas the 6-min walking test evaluates sub-
maximal exercise that is more similar to daily work;
these differences might affect the results. Another
possibility is that patients with ILD, other than IPF,
were also included in Chang’s study, which might
explain this difference.
Chang et al.8 also reported no association
between PaO2 at rest and the HRQoL score for ILD
patients. However, in our study, a significant
correlation was found between the two. The fact
that the mean PaO2 value in the present study was
11.0 kPa implies that mild hypoxemia at rest can
affect HRQoL. It is possible that desaturation during
exercise or daily activities affect the HRQoL of
patients with IPF. Actually, the relationship be-
tween the lowest SpO2 during the exercise test and
SGRQ scores was significant. The lowest SpO2 during
ARTICLE IN PRESS
Table 4 Results of stepwise multiple regression analysis.
Symptoms Activity Impacts Total
VC (L) — — — —
TLC (L) 0.18 — — —
TL,CO (mL/min/mmHg) — — — —
PaO2 (kPa) — 0.19 — —
Peak VO2 (mL/min) — —
The lowest SpO2 during the exercise — — — —
BDI score 0.21 0.45 0.28 0.47
Cumulative R2 0.39 0.64 0.28 0.47
All values listed represent the coefficient of determination (R2). Missing values indicate that independent variables were not
statistically significant.
HRQoL in IPF patients 413the exercise test was more significantly correlated
with the BDI score than other variables such as
pulmonary function, TL,CO, PaO2 at rest, and
exercise capacity (data not shown), although PaO2
during the test was not measured in the present
study. It is natural that the baseline PaO2 value at
rest affects the degree of desaturation. Hence, a
lower level of PaO2 at rest may cause more severe
hypoxemia during exercise or daily living, thus
increasing dyspnoea and worsening HRQoL.
Although further study is needed to clarify the
relationship between desaturation during exercise
or daily living and HRQoL in patients with IPF, our
results suggest that PaO2 at rest as well as during
exercise is important for HRQoL in IPF. Further-
more, the results of the present study also imply
that supplemental oxygen during exercise can
increase HRQoL in IPF patients, although this has
not yet been proven even in COPD patients.18
Regarding COPD, exercise capacity is known to be
one of the factors that markedly influences
HRQoL.11 It is also known that PaO2 at rest was
not correlated with the HRQoL score in most
previous studies except one.9,19 Peak _VO2 did not
correlate with SGRQ scores in the present study,
while PaO2 at rest correlated with HRQoL for the
IPF patients. This is of considerable interest, since
just the opposite has been proven to be true in
COPD patients.9,11 Although the mechanisms of
dyspnoea are known to be multifactorial,20 factors
specific to COPD, such as dynamic hyperinflation,
may affect patients’ dyspnoea, thus worsening the
HRQoL.
Some limitations in this study must be men-
tioned. First, we included only patients with mild-
to-moderate lung impairment (VC; 76.6716.8%).
Hence, it is unclear whether it is appropriate to
apply the present results to more severe cases.
Secondly, not all patients were diagnosed patholo-gically. Some reports, however, demonstrated that
the accuracy of thin-section CT in identifying IPF is
high.12,21 The patients diagnosed with IPF clinically
and who were included in the present study are
highly likely to be patients with IPF rather than
other diseases. Thirdly, we did not evaluate
depressive symptoms using specific questionnaires.
In regard to sarcoidosis, which is considered to be
one of ILDs, HRQoL has been demonstrated to be
disturbed22 and depressive symptoms were most
correlated with HRQoL score.23,24 The same thing
has also been demonstrated in COPD patients.11 It
is possible that the degree of depression also might
affect HRQoL in patients with IPF. Next, although
the validity of the SGRQ for patients with IPF has
been proven in a previous study,8 its responsiveness
has not yet been established. Therefore, the utility
of the SGRQ for patients with IPF has yet to be fully
elucidated, suggesting that further studies are
needed to confirm the responsiveness of the
questionnaire for patients with IPF or ILD. Finally,
because there have been no specific questionnaires
for IPF, it might be possible that patients with IPF
experience some symptoms or feelings that are
specific for IPF and these can be uncovered by the
questionnaire which was developed for patients
with COPD. Although we substituted the SGRQ,
which was already validated for COPD, developing a
questionnaire that covers all aspects of patients
with IPF is ideal for evaluating the real HRQoL
in IPF.
In summary, we used the SGRQ to evaluate IPF
patients and to identify the factors related to their
HRQoL. TLC, TL,CO, PaO2 at rest, the lowest SpO2
during the exercise test, and the BDI score were
significantly correlated with the total SGRQ score.
The BDI score in particular was the most signifi-
cantly correlated factor among these variables. A
similar tendency was observed in all three compo-
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O. Nishiyama et al.414nents of the score, i.e., symptoms, activity, and
impacts. Peak _VO2 was not correlated with any of
the SGRQ scores. In a stepwise multiple regression
analysis, the BDI score was selected as the only
factor contributing to the total score. Moreover,
the variables that were correlated with the HRQoL
of IPF patients were quite different from those in
COPD patients. Notably, managing patient dys-
pnoea should be given greater priority in clinical
settings involving IPF patients.Acknowledgements
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